Home ›
Leukemia Trials ›
NCT06566742
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Trial Details
NCT ID NCT06566742
Phase PHASE2
Sponsor M.D. Anderson Cancer Center
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Miami, Florida, United States|25.77427,-80.19366 Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
To be considered eligible to participate in this study, a patient must meet ALL inclusion criteria as follows: Pathologically proven CCUS or lower-risk MDS/CMML. CCUS is defined as the presence of cytopenia (absolute neutrophil count \< 1.8 x 10\^9/L, hemoglobin \< 13 g/dL in males or \< 12 g/dL in females, … Lower-risk MDS/CMML includes patients with International Prognostic Scoring System (IPSS) low- or intermediate-1-risk disease and Revised IPSS (IPS…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →